News & Events Year None202120202019201820172016201520142013201220112009 11/22/21 REGENXBIO Announces Orphan Drug Designation Granted to RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy 11/12/21 REGENXBIO Presents Additional Positive Interim Data from Trials of RGX-314 in Wet AMD and Diabetic Retinopathy Using Suprachoroidal Delivery at AAO 2021 11/09/21 REGENXBIO Announces Closing of Eye Care Collaboration Agreement with AbbVie 11/08/21 REGENXBIO to Participate in Upcoming Investor Conferences 11/05/21 REGENXBIO Announces RGX-314 Data Presentation at the American Academy of Ophthalmology 2021 Annual Meeting 11/02/21 REGENXBIO Reports Third Quarter 2021 Financial Results and Operational Highlights 11/02/21 Pathway Development Consortium Releases Draft White Paper to Facilitate AAV Gene Therapy Development Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Next page next › Last page last »
